論文 - 詳細
| RRC ID | 73160 |
|---|---|
| 著者 | Shimizu K, Ueda S, Kawamura M, Satoh M, Fujii SI. |
| タイトル | A single immunization with cellular vaccine confers dual protection against SARS-CoV-2 and cancer. |
| ジャーナル | Cancer Sci |
| Abstract |
The efficacy of current coronavirus disease 2019 (COVID-19) vaccines has been demonstrated; however, emerging evidence suggests insufficient protection in certain immunocompromised cancer patients. We previously developed a cell-based anti-cancer vaccine platform involving artificial adjuvant vector cells (aAVCs) capable of inducing a strong adaptive response by enhancing the innate immunity. aAVCs are target antigen-transfected allogenic cells that simultaneously express the natural killer T-cell ligand-CD1d complex on their surface. In the present study, we applied this system for targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (CoV-2-S) using CoV-2-S-expressing aAVCs (aAVC-CoV-2) and evaluated the immune response in a murine model. A single dose of aAVC-CoV-2 induced a large amount of CoV-2-S-specific, multifunctional CTLs in addition to CD4+ T-cell-dependent anti-CoV-2-S-specific Abs. CoV-2-S-specific CTLs infiltrated the lung parenchyma and persisted as long-term memory T cells. Furthermore, we immunized mice with CoV-2-S- and tumor-associated antigen (TAA)-co-expressing aAVCs (aAVC-TAA/CoV-2) and evaluated whether the anti-SARS-CoV-2 and antitumor CTLs were elicited. We found that the aAVC-TAA/CoV-2-S therapy exerted apparent antitumor effects and induced CoV-2-S-specific CTLs. These findings suggest aAVC-TAA/CoV-2-S therapy as a promising vaccine candidate for preventing COVID-19, as well as enhancing the effectiveness of cancer therapies. |
| 巻・号 | 113(8) |
| ページ | 2536-2547 |
| 公開日 | 2022-8-1 |
| DOI | 10.1111/cas.15434 |
| PMID | 35598170 |
| PMC | PMC9348309 |
| MeSH | Adjuvants, Immunologic Animals Antibodies, Neutralizing Antibodies, Viral COVID-19* / prevention & control Immunization Mice Neoplasms* SARS-CoV-2 Vaccination Viral Vaccines* |
| IF | 4.966 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | X(Twitter) |
| 各媒体での言及数の合計 | 3 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | NIH3T3 |